Kamada Ltd.

Foreign Filer Report • Mar 5, 2014

_________ false

C002����� ��"�2PublicKAMADA LTD9024Corporation no: 511524605Stock Exchange/Market: -11934380Sapir 7 P.O.B 4081 , Ness-Ziona 74036 , ISRAEL ,Tel: 08-9406472 , Fax: 08-9406473E.mail address: liatc@kamada.comReported via MAGNA: 05/03/2014              Time of broadcast: 13:27 13:25:53

Company site:		www.kamada.com

Reference: 2014-02-006078

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on Kamada Initiates Phase 2/3 Clinical Trial of Glassia to Treat Newly Diagnosed Pediatric Patients with Type 1 Diabetes
KMDA_Form_6K_initiation_of_T1D_trial_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity:
Date of revision of form structure: 02/03/2014
- - -
Name of the Signatory: : Cohen Liat , Position of Signatory in the reporting corporation: Company Controller , Name of Employer Company: .
Sapir Telephone: 08-9913168 , Facsimile: 08-9912183 , E-mail: liatc@kamada.com 1